AVROBIO

AVROBIO’s team of renowned industry leaders formed the company in 2015 to accelerate development of two novel cell and gene therapies pioneered in labs at the University Health Network in Toronto, ON. The Company’s highly efficient gene delivery system enables a patient’s cells to be modified to deliver novel genes that cure serious diseases. AVROBIO went public in June 2018 (NASDAQ: AVRO).

Headquarters Cambridge, MA & Toronto, ON
Website www.avrobio.com
Pipeline Two Phase 1 programs, one in Fabry Disease and one in AML
Partners Center for Commercialization of Regenerative Medicine (CCRM)
Twitter @avrobio